Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Delcath Systems ( (DCTH) ) has shared an update.
Delcath Systems announced preliminary, unaudited financial results for the fourth quarter and full year 2024, reporting expected revenues of $15.1 million for the quarter and $37.2 million for the year. The company highlighted strong sales from its HEPZATO KIT, and maintained a robust cash position of $53.2 million with no debt, suggesting stable financial health and positive operational performance going forward.
More about Delcath Systems
Delcath Systems, Inc. is an interventional oncology company specializing in treatments for primary and metastatic liver cancers. Its main products are the HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System, designed to administer high-dose chemotherapy to the liver with controlled systemic exposure.
YTD Price Performance: -8.96%
Average Trading Volume: 399,690
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $367.1M
Learn more about DCTH stock on TipRanks’ Stock Analysis page.
